Kondo S, Noguchi M, Funakoshi T, Fujikawa K, Kisiel W
Department of Pathology, University of New Mexico School of Medicine, Albuquerque.
Thromb Res. 1987 Nov 15;48(4):449-59. doi: 10.1016/0049-3848(87)90402-6.
Previous studies indicated that human placental anticoagulant protein, a member of the lipocortin family, prolonged the clotting time of normal plasma when clotting was induced by brain thromboplastin or by kaolin in the presence of cephalin and calcium. Using a two-stage amidolytic assay to assess factor X activation and a tritiated peptide release assay to assess factor IX activation, we have examined the ability of purified preparations of placental anticoagulant protein (Mr = 36.5 kDa) to inhibit the activation of either factor X or factor IX by a complex of human factor VIIa-tissue factor. Placental anticoagulant protein markedly inhibits factor X and factor IX activation by factor VIIa-tissue factor in a non-competitive manner with Ki values of 40 nM and 70 nM, respectively. Placental anticoagulant protein had no effect on factor Xa amidolytic activity, and its inhibitory activity was not diminished by prior incubation with antibody raised against partially purified plasma extrinsic pathway inhibitor. Binding of placental anticoagulant protein to phospholipid vesicles, crude tissue factor and purified, relipidated human brain tissue factor apoprotein was observed only in the presence of calcium ions. These results indicate that placental anticoagulant protein is a potent factor VIIa-tissue factor inhibitor and suggests that its mechanism of action involves binding to the phospholipid portion of the tissue factor lipoprotein.
先前的研究表明,人胎盘抗凝蛋白作为脂皮质素家族的一员,当在脑凝血活酶或高岭土存在且有脑磷脂和钙的情况下诱导凝血时,它会延长正常血浆的凝血时间。我们使用两阶段酰胺水解测定法评估因子X的激活,并用氚标记肽释放测定法评估因子IX的激活,研究了纯化的胎盘抗凝蛋白制剂(分子量 = 36.5 kDa)抑制人因子VIIa - 组织因子复合物激活因子X或因子IX的能力。胎盘抗凝蛋白以非竞争性方式显著抑制因子VIIa - 组织因子对因子X和因子IX的激活,其抑制常数(Ki)值分别为40 nM和70 nM。胎盘抗凝蛋白对因子Xa的酰胺水解活性没有影响,并且其抑制活性不会因预先与针对部分纯化的血浆外源性途径抑制剂产生的抗体孵育而降低。仅在存在钙离子的情况下,观察到胎盘抗凝蛋白与磷脂囊泡、粗制组织因子以及纯化的、重新脂质化的人脑组织因子载脂蛋白结合。这些结果表明,胎盘抗凝蛋白是一种有效的因子VIIa - 组织因子抑制剂,并提示其作用机制涉及与组织因子脂蛋白的磷脂部分结合。